We are pleased to provide our investors with our December 2021 Investor Newsletter.
In this edition, our Executive Director and CEO Bob Proulx gives an update on our recent activities, highlighting the progress in our MagSense Phase 1 clinical trial.
You can also read more from the Principal Investigator for our study at Lake Macquarie, an introduction to our new Director of Operations, Carmen Soikowski, and other relevant company news – including a look at our new facility.
We thank you for your continued support of our company and the work we are doing to develop our technology.
Imagion Biosystems normally distributes this update as an e-newsletter. Investors can sign up to receive email updates at this link: http://ems.gs/3FuT0frcGxD
Please click to review the newsletter.
